The Patent Finder

Terms ending in 2039

Immunocore Limited

Every in-force patent on Immunocore Limited's record whose computed term ends in 2039, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleHolderStatusExpiresConfidence
US 11,639,374T Cell Receptors Specific for the NY-ESO-1 Tumor ANTIGEN-HLA-A*02 Complex
In force
 · High confidence
Immunocore LimitedIn forceHigh confidence
US 11,440,944Engineered Immune-Mobilizing T-Cell Receptors with Enhanced Affinity for HIV-1 Gag
In force
 · High confidence
Immunocore LimitedIn forceHigh confidence
US 12,606,607T Cell Receptors
In force
 · High confidence
Immunocore LimitedIn forceHigh confidence
US 11,827,688Dosing Regimen for GP100-Specific TCR - ANTI-CD3 SCFV Fusion Protein
In force
 · High confidence
Immunocore LimitedIn forceHigh confidence
4 of 4 patents shown. Soonest term end first, then patent number.
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited